ID: ALA4168689

Max Phase: Preclinical

Molecular Formula: C16H19F3N2O4

Molecular Weight: 360.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(/C=C/c1ccc(C(F)(F)F)cc1)NC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C16H19F3N2O4/c17-16(18,19)10-4-1-9(2-5-10)3-6-13(23)21-7-11-14(24)15(25)12(22)8-20-11/h1-6,11-12,14-15,20,22,24-25H,7-8H2,(H,21,23)/b6-3+/t11-,12+,14+,15-/m1/s1

Standard InChI Key:  ZVPFOBWIGFRKAS-OXMRTWMISA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 360.33

Molecular Weight (Monoisotopic): 360.1297

AlogP: -0.11

#Rotatable Bonds: 4

Polar Surface Area: 101.82

Molecular Species: NEUTRAL

HBA: 5

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.91

CX Basic pKa: 7.85

CX LogP: 0.06

CX LogD: -0.52

Aromatic Rings: 1

Heavy Atoms: 25

QED Weighted: 0.48

Np Likeness Score: 0.34

References

1. Li HY, Lee JD, Chen CW, Sun YC, Cheng WC..  (2018)  Synthesis of (3S,4S,5S)-trihydroxylpiperidine derivatives as enzyme stabilizers to improve therapeutic enzyme activity in Fabry patient cell lines.,  144  [PMID:29289886] [10.1016/j.ejmech.2017.12.036]

Source

Source(1):

• Scientific Literature